227 related articles for article (PubMed ID: 27462924)
1. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.
Yin JY; Li X; Zhou HH; Liu ZQ
Pharmacogenomics; 2016 Aug; 17(12):1365-78. PubMed ID: 27462924
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of platinum-based chemotherapy in NSCLC.
Hildebrandt MA; Gu J; Wu X
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):745-55. PubMed ID: 19442035
[TBL] [Abstract][Full Text] [Related]
3. Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer.
Liu L; Wu J; Zhong R; Wu C; Zou L; Yang B; Chen W; Zhu B; Duan S; Yu D; Tan W; Nie S; Lin D; Miao X
Mol Carcinog; 2013 Dec; 52(12):923-31. PubMed ID: 22821704
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
[TBL] [Abstract][Full Text] [Related]
5. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.
Yin JY; Li X; Li XP; Xiao L; Zheng W; Chen J; Mao CX; Fang C; Cui JJ; Guo CX; Zhang W; Gao Y; Zhang CF; Chen ZH; Zhou H; Zhou HH; Liu ZQ
Cancer Lett; 2016 Jul; 377(1):65-73. PubMed ID: 27126360
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.
Xu X; Duan L; Zhou B; Ma R; Zhou H; Liu Z
Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):786-92. PubMed ID: 22725681
[TBL] [Abstract][Full Text] [Related]
7. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.
Rossi A; Di Maio M
Expert Rev Anticancer Ther; 2016 Jun; 16(6):653-60. PubMed ID: 27010977
[TBL] [Abstract][Full Text] [Related]
8. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer.
Rose MC; Kostyanovskaya E; Huang RS
Genomics Proteomics Bioinformatics; 2014 Oct; 12(5):198-209. PubMed ID: 25449594
[TBL] [Abstract][Full Text] [Related]
10. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer.
Okuda K; Sasaki H; Hikosaka Y; Kawano O; Yukiue H; Yano M; Fujii Y
J Surg Res; 2011 Jun; 168(2):206-12. PubMed ID: 20070981
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
12. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
Zhang L; Ma W; Li Y; Wu J; Shi GY
Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis.
Chen J; Wang Z; Zou T; Cui J; Yin J; Zheng W; Jiang W; Zhou H; Liu Z
Oncotarget; 2016 Aug; 7(34):55741-55756. PubMed ID: 27248474
[TBL] [Abstract][Full Text] [Related]
16. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
He C; Duan Z; Li P; Xu Q; Yuan Y
Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
[TBL] [Abstract][Full Text] [Related]
17. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
18. [Advances in Association of Estrogen and Human Non-small Cell Lung Cancer].
He J; Song X
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):315-20. PubMed ID: 25975303
[TBL] [Abstract][Full Text] [Related]
19. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer.
KimCurran V; Zhou C; Schmid-Bindert G; Shengxiang R; Zhou S; Zhang L; Zhang J
Adv Med Sci; 2011; 56(1):30-8. PubMed ID: 21536539
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.
Mlak R; Krawczyk P; Ciesielka M; Homa I; Powrózek T; Prendecka M; Kozioł P; Milanowski J; Małecka-Massalska T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):621-9. PubMed ID: 26220844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
